Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy

Author:

Mo Han-Yue,Liao Ying-Yang,You Xue-Mei,Cucchetti Alessandro,Yuan Bao-Hong,Li Ru-Hong,Zhong Jian-HongORCID,Li Le-Qun

Funder

the Guangxi University of Science and Technology Research Projects

the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province

the Innovation Project of Guangxi Graduate Education

Guangxi Science and Technology Development Projects

the National Science and Technology Major Special Project

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference56 articles.

1. Cancer Statistics, 2017;RL Siegel;CA Cancer J Clin,2017

2. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study;JH Zhong;Oncotarget,2017

3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;Eur J Cancer,2012

4. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria;KC Lim;Br J Surg,2012

5. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis;Z Guo;Ann Surg Oncol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3